IRIS develops technologies for in-depth, individualized analysis enabling faster and more effective interventions and prevention in the field of personalized and targeted medicine. IRIS has earned six US patents and a portfolio of patents worldwide. IRIS has multiple patents on "Artificial Intelligence System for Genetic Analysis."

On 4/9/2014, the company founded its subsidiary, IRIS Wellness Labs, to launch products and services.  To learn more about the people IRIS Wellness Labs has helped and how we are making strides in advancing the medical industry, please visit

https://iriswellnesslabs.com/people-we-have-helped/

https://iriswellnesslabs.com/news-and-media/

Thank you for your interest in IRIS Biotechnologies and IRIS Wellness Labs.

TECHNOLOGY INNOVATION LEADER

IRIS received Frost and Sullivan’s coveted North American Technology Innovation Award in Pharmacogenomics.  

US GOVERNMENT AND GLOBAL RECOGNITION

IRIS received a QTDP grant after NIH funding recommendation and an IAIR Award for Best Company for Leadership in Personalized Medicine in North America.

LIFE SCIENCES INDUSTRY RECOGNITION

IRIS' President and CEO, Simon Chin, was recognized by PharmaVOICE as one of the 100 most inspirational people in the life sciences industry.